What's New in MG Research: Descartes-08, and RNA CAR T-cell (rCAR-T) therapy for generalized myasthenia gravis and other autoimmune conditions
Speaker: Miloš Miljković, MD MSc
Abstract: In a Phase 2 clinical trial, Descartes-08 — an RNA CAR T-cell (rCAR-T) therapy — appeared to be safe and able to achieve deep and sustained responses in patients with generalized myasthenia gravis. We will discuss results of the trial, and plans for further development of Descartes-08 for myasthenia gravis and other autoimmune diseases.
Speaker Bio: Dr. Miljković is the Chief Medical Officer of Cartesian Therapeutics. He is board-certified in hematology, medical oncology, and internal medicine. Prior to joining Cartesian, he was at the National Cancer Institute for over seven years, where as Staff Clinician he specialized in early-stage trials in immuno-oncology. Dr. Miljković has served as Principal Investigator on 6 clinical trials of immunotherapy and targeted agents and as Associate Investigator on more than 20 others. He completed residency at the Johns Hopkins University and Sinai Hospital of Baltimore program in internal medicine, followed by clinical and research fellowships in the joint NCI/NHLBI program at the NIH, where he also served as Chief Fellow.